Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00348933 · ClinicalTrials.gov registry record · NA

Dietary Supplements for the Treatment of Angelman Syndrome

A NA study of Nervous System Diseases and Angelman Syndrome, sponsored by University of California, San Diego.

Completed
Registry status
NA
Development phase
90
Enrollment target
4
Study locations

NCT00348933 is a NA study of Nervous System Diseases and Angelman Syndrome that has completed, run by University of California, San Diego. The registered enrollment target is 90 participants, below the 320-participant average among 23 other Nervous System Diseases trials with a reported enrollment target (72% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00348933, a NA study of Nervous System Diseases and Angelman Syndrome, has completed, sponsored by University of California, San Diego.

COMPLETED
Registry status
NA
Development phase
90 participants
Enrollment target
4
Study locations

Study Summary

Angelman syndrome (AS) is a complex genetic disorder that affects the nervous system. The purpose of this study is to determine the effectiveness of certain dietary supplements in treating the symptoms of AS.

Interventions

  • DRUG Betaine
  • DRUG Creatine
  • DRUG Metafolin
  • DRUG Vitamin B12

Study Locations (4)

California

  • Rady Children's Hospital San Diego - San Diego

Massachusetts

  • Children's Hospital Boston - Boston

South Carolina

  • Greenwood Genetics Center - Greenwood

Texas

  • Baylor College of Medicine - Houston

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2006-07
Est. Completion 2010-02
Phase NA

Sponsor

University of California, San Diego

775 total trials

What the Registry Record Tells You About NCT00348933

The ClinicalTrials.gov registry entry for NCT00348933 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 320-participant average among 23 other Nervous System Diseases trials with a reported enrollment target (72% lower). The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Nervous System Diseases appearing as the primary indexed condition, and to 4 interventions - of which Betaine is the first listed.

NCT00348933 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Massachusetts, South Carolina.

Frequently Asked Questions

What is clinical trial NCT00348933 about?

NCT00348933 is a clinical study titled "Dietary Supplements for the Treatment of Angelman Syndrome". Angelman syndrome (AS) is a complex genetic disorder that affects the nervous system. The purpose of this study is to determine the effectiveness of certain dietary supplements in treating the symptoms of AS.

What is the current status of trial NCT00348933?

This trial is currently completed. It is a NA study. The enrollment target is 90 participants. The study started on 2006-07. Estimated completion is 2010-02.

What conditions does trial NCT00348933 study?

This clinical trial studies the following conditions: Nervous System Diseases, Angelman Syndrome.

What interventions are being tested in trial NCT00348933?

The interventions under investigation include: Betaine (DRUG), Creatine (DRUG), Metafolin (DRUG), Vitamin B12 (DRUG).

Who is sponsoring clinical trial NCT00348933?

This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00348933 being conducted?

This trial has 4 study locations across California, Massachusetts, South Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Nervous System Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.